Drug Watch a heads-up on pharmaceuticals in late-stage development

New drugs Product type/proposed indication FDA status/notes

abagovomab
Menarini Group
an anti-idiotype antibody, able to mimic a tumor antigen
highly expressed by ovarian cancer cells/used to prevent
or delay the tumor relapse in patients whose disease
responded to the first-line chemotherapy by activating
an immune response toward cancer cells
phase 2/3

karenitecin/BNP1350
BioNumerick Pharmecuticals
in the camptothecin class of chemotherapy drugs/
treatment of advanced ovarian cancer
phase 3

pazopanib (Votrient)
GlaxoSmithKline
multi-kinase angiogenesis inhibitor/maintenance therapy
for the treatment of ovarian cancer
phase 3
 references/sources: